| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The cestode parasite Taenia solium causes human neurocysticercosis, the most important cause of seizure disorders worldwide.1 While most commonly occurring in the developing world, this disease also occurs in industrialized countries due either to the immigration of already infected patients or through infections acquired by direct or indirect contact with individuals from disease-endemic regions who harbor the adult parasite.2 Taenia solium is transmitted from pigs, which harbor the larval parasites in their muscles as intermediate hosts, to humans, the definitive hosts who have adult tapeworms in their intestines. Pigs become infected by ingesting T. solium eggs in the feces of a person carrying the tapeworm. Humans become infected with intestinal tapeworms after ingesting raw or incompletely cooked infected pig meat. The clinical significance of the parasite to humans is not because of infection with the adult tapeworm, but because ingested tapeworm eggs leads to hematogenously disseminated larval cysts. When located in the central nervous system, these cysts cause neurocysticercosis, characterized by seizure disorders, psychiatric disturbance, hydrocephalus, and other neurologic conditions.
Transmission of T. solium has decreased or been eliminated in much of the first world over the last century as a result of improvements in general sanitation and public health. However, similar improvements in public living conditions are unlikely to occur in the short term in much of the developing world where cysticercosis is highly endemic, and other parasite control measures are required to have a more immediate impact on the prevalence of this disease. Neurocysticercosis is potentially eradicable3 since inexpensive and highly effective anthelmintics are available that could potentially be used to eliminate human tapeworm infections. To date, these measures have not achieved sustainable control of T. solium transmission. One major barrier of the use of anthelmintics to control T. solium is that despite the elimination of tapeworm carriers by, for example, mass treatment of the population with drugs to remove tapeworms, pig infection will remain. This reservoir of infection can readily establish new tapeworm infections of humans and renewed disease transmission.
We have sought to develop a vaccine to prevent T. solium infection of pigs, thereby removing the source of T. solium tapeworm infections for humans.4 Proteins contained within the parasite eggs (known as oncospheres) are known to be a source of protective antigens.5,6 Furthermore, recombinant oncosphere antigens have been found to be highly effective as vaccines for prevention of infections with closely related parasites of sheep and cattle.7 Taenia solium homologs of the protective antigens for these veterinary parasites have been identified8,9 and recombinantly expressed in Escherichia coli.4,7 These recombinant vaccines (TSOL18 and TSOL45), produced as glutathione-S-transferase (GST) fusion proteins, were recently found to have high efficacy in preventing pig infections in experimental trials in Mexico and Cameroon.4 Here we describe efficacy results of a TSOL18 and TSOL45 vaccination trial of pigs in Peru, with in vitro correlates of immunity performed by immunoblotting.
Twenty six three-month-old pigs (14 males and 12 females, Pietrain/Landrace mixed breed) were used in the vaccine trial. All vaccinations were given with 1 mg of Quil A (Superflos Biosector, Vedbaek, Denmark) as adjuvant. Two groups of eight pigs each were vaccinated with either TSOL18 or TSOL45. TSOL18 was given as a GST fusion protein4 (two 200-µg doses spaced four weeks apart). TSOL45 was given as two injections of 200 µg as a GST fusion protein4 spaced four weeks apart, and an additional injection of 200 µg as a recombinant maltose binding protein (MBP) fusion protein4 two weeks later. Five control pigs were immunized with 200 µg of recombinant GST only (two doses spaced four weeks apart), and a second group of five control pigs received successively two immunizations of 200 µg of GST spaced four weeks and one immunization two weeks later with 200 µg of recombinant MBP. Ten days after their final immunization, all pigs received an oral challenge infection with one full gravid T. solium proglottid obtained from treatment of tapeworm carriers in the previous three weeks and stored in glycerol. Twelve weeks after the challenge infection, pigs were humanely killed and the entire carcass and brain were assessed for the presence and viability of cysticerci.6 Parasites were classified as viable if a defined cystic structure with liquid content was still present, and degenerate if this had been replaced by semi-solid contents or an inflammatory scar. The study was reviewed and approved by the Animal Ethics Committee of the School of Veterinary Medicine, Universidad de San Marcos, Lima, Peru and the Johns Hopkins School of Public Health. Details of the immunization schedule and parasite/cyst loads of pigs after challenge infection are shown in Table 1
.
|
To determine whether the TSOL18 or TSOL45 vaccines induced antibodies that recognized native T. solium oncosphere proteins, sera from vaccinated and control pigs were analyzed by immunoblot, using an assay we have previously published.6 Antisera against TSOL18 reacted with a single antigen of approximately 20 kD, while antisera raised to TSOL45 identified three prominent bands with sizes of 35, 38, and 39 kD, and showed less prominent reactivity against 20-kD and 25-kD antigens. Pre-immunization control sera showed a thin reactive band at 20 kDa, indistinguisable in altitude from the 20 kDa antibody band obtained in response to TSOL18 (Figure 1). The size of the above native antigens is larger than the sizes predicted by the associated cDNAs, possibly due to glycosylation at predicted N-linked glycosylation sites.8,9 The detection of several oncosphere antigens with antisera raised against TSOL45 is consistent with the previously published observation that the gene encoding this protein is transcribed into three differentially spliced mRNAs.8 The antigens recognized by antisera against TSOL45 appeared to correspond to relatively prominent components detected by antisera raised against whole oncosphere extract (lane 4 in Figure 1).6 However, the component detected with antisera raised against TSOL18 did not correspond to any of the dominant specificities detected by pigs vaccinated and protected6 by immunization with whole oncosphere extract, possibly due to cleavage of a larger antigen.
|
Received September 14, 2004. Accepted for publication November 29, 2004.
Acknowledgments: We thank Dr. Teresa Bernal, Dr. Cesar Gavidia, and Dr. Nestor Falcon for performing the necropsy procedures.
Financial support: Ongoing cysticercosis research by the authors was supported by the research grants from the National Health and Medical Research Council, Australia (Marshall W. Lightowlers), the National Institutes of Health (Armando E. Gonzalez and Robert H. Gilman), The Wellcome Trust (Armando E. Gonzalez, Robert H. Gilman, Victor C. W. Tsang, and Hector H. Garcia), the Food and Drug Administration (Hector H. Garcia), and the Bill and Melinda Gates Foundation (Armando E. Gonzalez, Robert H. Gilman, Victor C. W. Tsang, and Hector H. Garcia).
Authors’ addresses: Armando E. Gonzalez, School of Veterinary Medicine, Universidad Nacional Mayor de San Marcos, Av. Circunvalacion s/n, Salamanca de Monterrico, Ate, Lima, Peru, E-mail: emico{at}terra.com.pe. Charles G. Gauci, Dylan Barber, and Marshall W. Lightowlers, Veterinary Clinical Centre, The University of Melbourne, 250 Princes Highway, Werribee, Victoria 3030, Australia, E-mails: charlesg{at}unimelb.edu.au, dylanbarber{at}hotmail.com, and marshall{at}unimelb.edu.au. Robert H. Gilman, Department of International Health, Johns Hopkins University Bloomberg School of Public Health, North Wolfe Street, Baltimore, MD 21205, E-mail: rgilman{at}jhsph.edu. Victor C. W. Tsang, Immunology Branch, Division of Parasitic Diseases, National Centers for Infectious Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, Mailstop F-13, Atlanta, GA 30341-3724, E-mail: vct1{at}cdc.gov. Hector H. Garcia, Department of Microbiology, Universidad Peruana Cayetano Heredia, Lima, Peru and Cysticercosis Unit, Instituto de Ciencias Neurologicas, Jr. Ancash 1271, Barrios Altos, Lima 1, Peru, Telephone: 51-1-328-7360, Fax: 51-1-328-4038, E-mail: hgarcia{at}jhsph.edu. Manuela Verastegui, Department of Microbiology, Universidad Peruana Cayetano Heredia, Av. H. Delgado 430, Urb. Ingenieria, SMP, Lima 31, Peru, E-mail: mveraste{at}jhsph.edu.
Reprint requests: Marshall W. Lightowlers, Veterinary Clinical Centre, The University of Melbourne, 250 Princes Highway Werribee, Victoria 3030, Australia.
This article has been cited by other articles:
|
|
 |
|
  Y. Zheng, X. Cai, X. Luo, D. Zhang, and Z. Jing Genetic Variability of the 45W Gene Family between Chinese and Mexican Taenia solium Am J Trop Med Hyg, June 1, 2008; 78(6): 946 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H Garcia, A. E Gonzalez, V. C W Tsang, R. H Gilman, and for the Cysticerocosis Working Group in Peru Neurocysticercosis: some of the essentials Practical Neurology, October 1, 2006; 6(5): 288 - 297. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
